Clinical Trials Browser

NIH × Oligodendroglioma × Bevacizumab × Clear all

NCT01648348 2018-05-23

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

Phase 1/2 Completed

116 enrolled 17 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

NCT01189240 2015-12-14

RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma

Phase 1/2 Terminated

13 enrolled 13 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00667394 2015-11-05

Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors

Phase 2 Completed

42 enrolled 11 charts

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00492089 2014-05-09

Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer

Phase 2 Completed

11 enrolled 7 charts

Hemangiopericytoma, Malignant, Squamous Cell Carcinoma of Head and Neck, Astrocytoma, Brain Neoplasms, Ependymoma, Glioma, Meningioma, Neoplasms, Oligodendroglioma, Pinealoma, Radiation Injuries, Salivary Gland Neoplasms, Choroid Plexus Neoplasms, Esthesioneuroblastoma, Olfactory